Global Diabetes Survey—An annual report on quality of diabetes care

Schwarz, Peter E. H.; Gallein, Gregor; Ebermann, Doreen; Müller, Andreas; Lindner, Antje; Rothe, Ulrike; Nebel, Istvan Tibor; Müller, Gabriele

doi:10.1016/j.diabres.2012.11.008

Cited by 41 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 The six markers we used included: (1) appointment adherence, (2) patient-provider communication, (3) diabetes education during clinic visit, (4) congruency with standards of care, (5) diabetes selfmanagement behaviors, and (6) diabetes-related hospitalizations. Each caregiver completed the survey onsite during a clinical research center visit.…”

Section: Qoc Markersmentioning

confidence: 99%

Quality of care in rural youth with type 1 diabetes: a cross-sectional pilot assessment

Stumetz

Yi‐Frazier²,

Mitrovich

et al. 2016

BMJ Open Diab Res Care

View full text Add to dashboard Cite

BackgroundType 1 diabetes mellitus (T1DM) presents a significant health burden for patients and families. The quality of care (QOC) among those living in rural communities is thought to be subpar compared with those in urban communities; however, little data exist to reflect this, especially in pediatric diabetes.ObjectiveThe purpose of this pilot study was to investigate diabetes QOC among families living in rural versus urban areas. 6 QOC markers were used to compare youth with T1DM: appointment adherence, patient–provider communication, diabetes education during clinic visit, congruency with diabetes standards of care, diabetes self-management behaviors, and diabetes-related hospitalizations.Research design and methodsParticipants were rural or urban adult caregivers of youth ages 2–18 with ≥10-month history of T1DM receiving treatment at Seattle Children's Hospital, USA. Participants were from rural areas of central Washington, or urban areas of western Washington. Caregivers completed a 26-item survey pertaining to the 6 QOC markers. The 6 QOC markers were compared across 61 participants (34 rural, 27 urban), to determine how diabetes care quality and experiences differed. Data were collected over 12 months. Groups were compared using t-tests and χ2 tests, as appropriate.ResultsCompared with urban families, rural families reported significantly lower income and a 4-fold greater usage of public insurance. Among the QOC measures, rural participants were significantly worse off in the appointment adherence, patient–provider communication, and hospitalizations categories. Congruence with diabetes standards of care (foot care only) was also significantly poorer in rural participants.ConclusionsThe burden of travel in conjunction with the lack of resources in this rural population of families with T1DM youth is cause for concern and warrants further research.

show abstract

Section: Qoc Markersmentioning

confidence: 99%

Quality of care in rural youth with type 1 diabetes: a cross-sectional pilot assessment

Stumetz

Yi‐Frazier²,

Mitrovich

et al. 2016

BMJ Open Diab Res Care

View full text Add to dashboard Cite

show abstract

“…The disease is characterized by alteration in the carbohydrate metabolism resulting in an increase of the glucose levels [19]. Approximately 360 million of adult people have diabetes, corresponding to 8.3% of the world with diabetes, and this is projected to rise to 552 million by 2030, corresponding to 9.9% of the world population [20]. The hyperglycemia in diabetes produces superoxide anions, which generate hydroxyl radicals, promoting cell membrane damages as a result of lipid peroxidation and protein glycation of membrane [18].…”

Section: Introductionmentioning

confidence: 99%

Lectin fromCrataeva tapiaBark Improves Tissue Damages and Plasma Hyperglycemia in Alloxan-Induced Diabetic Mice

Rocha

Araújo²,

Fonseca³

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Crataeva tapia is a plant popularly used for diabetes treatment, in Brazil. Progressive decline in renal and hepatic functions has been described in patients with diabetes mellitus, and mortality rate is increased in patients with chronic liver and renal disease. This study aimed to evaluate whether Crataeva tapia bark lectin (CrataBL) improves hyperglycemia and renal and hepatic damage in diabetic mice. CrataBL was purified by ion exchange chromatography on CM-cellulose, and intraperitoneal administration of CrataBL to alloxan-induced diabetic mice at dose of 10 mg/Kg/day and 20 mg/Kg/day for 10 days significantly reduced serum glucose levels by 14.9% and 55.9%, respectively. Serum urea, creatinine, aspartate aminotransferase, and alanine aminotransferase were also significantly reduced after treatment with both doses of CrataBL. Furthermore, histological analysis of liver, kidney, and pancreas revealed an improvement in the tissue morphology upon treatment with CrataBL. The results suggest that CrataBL has a beneficial hypoglycemic activity and improves the renal and hepatic complications of diabetes. Therefore, this lectin may be a promising agent for the treatment of diabetes, and this might be the basis for its use in the folk medicine as an alternative treatment to manage diabetes-related complications such as hyperglycemia and tissue damage.

show abstract

“…It has been estimated that 422 million adults are living with diabetes, with direct annual costs of more than $827 billion (1)(2)(3). As a result of hyperglycemia, hyperlipidemia, and impaired regenerative capacity in patients with diabetes, a wide range of complications have been commonly found, including heart attacks, strokes, defects in wound healing, and vision loss (4). Thus, identifying key molecules for improving regenerative capacity is critical for developing effective treatments for these diabetes-induced complications.…”

mentioning

confidence: 99%

MG53 Does Not Manifest the Development of Diabetes in db/db Mice

et al. 2020

View full text Add to dashboard Cite

MG53 is a member of the TRIM protein family that is predominantly expressed in striated muscles and participates in cell membrane repair. Controversy exists regarding MG53's role in insulin signaling and manifestation of diabetes. We generated db/db mice with either whole-body ablation or sustained elevation of MG53 in the bloodstream in order to evaluate the physiological function of MG53 in diabetes. To quantify the amount of MG53 protein in circulation, we developed a monoclonal antibody against MG53 with high specificity. Western blot using this antibody revealed lower or no change of serum MG53 levels in db/db mice or patients with diabetes compared with control subjects. Neither wholebody ablation of MG53 nor sustained elevation of MG53 in circulation altered insulin signaling and glucose handling in db/db mice. Instead, mice with ablation of MG53 were more susceptible to streptozotocin-induced dysfunctional handling of glucose compared with the wild-type littermates. Alkaline-induced corneal injury demonstrated delayed healing in db/db mice, which was restored by topical administration of recombinant human (rh)MG53. Daily intravenous administration of rhMG53 in rats at concentrations up to 10 mg/kg did not produce adverse effects on glucose handling. These findings challenge the hypothetical function of MG53 as a causative factor for the development of diabetes. Our data suggest that rhMG53 is a potentially safe and effective biologic to treat diabetic oculopathy in rodents.

show abstract

Global Diabetes Survey—An annual report on quality of diabetes care

Cited by 41 publications

References 18 publications

Quality of care in rural youth with type 1 diabetes: a cross-sectional pilot assessment

Quality of care in rural youth with type 1 diabetes: a cross-sectional pilot assessment

Lectin fromCrataeva tapiaBark Improves Tissue Damages and Plasma Hyperglycemia in Alloxan-Induced Diabetic Mice

MG53 Does Not Manifest the Development of Diabetes in db/db Mice

Contact Info

Product

Resources

About